Editorial: Towards Precision Nutrition: A Novel Multi-Dimensional Management Strategy for Chronic Kidney Disease Based on Biomarkers

Abstract

The visceral proteins albumin and prealbumin must be correctly recognized as inflammatory markers associated with "nutrition risk" in nutrition assessment. Serum albumin and prealbumin levels do not serve as proxy measures of total body protein or total muscle mass and are not useful monitoring parameters to guide nutrition support therapy. To identify these as markers of malnutrition is an oversimplification that should be avoided (3). Recent studies suggest that a comprehensive evaluation should integrate anthropometric parameters (weight, height, BMI), body composition indices (Lean Tissue Index LTI, Fat Tissue Index FTI), serum biochemical markers (e.g., albumin, prealbumin), the Dietary Inflammatory Index (DII), and clinical examinations.Incorporating ASM as part of body composition and muscle mass assessment is valuable, particularly for diagnosing sarcopenia. The DII is a comprehensive dietary assessment tool that quantifies the overall inflammatory potential of an individual's diet by scoring various pro-and anti-inflammatory food components. Adjusting dietary patterns to lower the DII score may serve as an effective intervention strategy to delay CKD progression. When managing nutrition for CKD patients, controlling the dietary inflammatory potential is as crucial as ensuring adequate nutrient intake. Early-stage CKD: Focus on an anti-inflammatory diet as the core strategy, controlling the DII score to delay the progression of a micro-inflammatory state. Plant dominant low-protein diets reduce the risk of developing incident CKD, CKD progression, and its related complications including cardiometabolic disease, metabolic acidosis, mineral and bone disorders, and uremic toxin generation (4). Simultaneously ensure adequate energy intake (30-35 kcal/kg/day) to delay disease progression and prevent malnutrition, while restricting sodium (<4 g/day) and phosphorus (<800 mg/day), and increasing dietary fiber to regulate gut microbiota (5). Attention should shift to specific nutrient supplementation to inhibit the overactivation of inflammatory pathways. Li et al. found that supplementing with Bailing capsules combined with low-calcium dialysate in peritoneal dialysis patients significantly slowed the decline of residual renal function and improved micro-inflammation and oxidative stress. Lee et al. further revealed that both baseline and longitudinal Retinol-Binding Protein 4 (RBP4) levels in maintenance hemodialysis patients were negatively correlated with all-cause mortality, with the low RBP4 group having a 2.44-fold increased risk of death. Muscle atrophy affects over 50% of CKD patients and is significantly associated with morbidity and mortality. ASM strongly correlates with anthropometric parameters (weight, BMI) and body composition (LTI, FTI), but not with renal function or traditional nutritional markers. This indicates that muscle loss occurs independently of conventional malnutrition indicators. Therefore, preventing and treating sarcopenia requires comprehensive strategies, including adequate high-quality protein intake, resistance exercise rehabilitation, vitamin D supplementation, and avoiding excessive protein restriction that could exacerbate muscle wasting. CKD nutritional management necessitates the integration of dietitians, rehabilitation therapists, and patient education. Future directions should include: Early Screening (Incorporate DII and body composition analysis into routine CKD assessments), Dynamic Monitoring (Adjust nutritional plans based on levels of RBP4 and inflammatory markers), and Whole-Process Management(Continuously optimize dietary structure and muscle mass maintenance from early CKD through the dialysis stage, dynamically adjusting strategies). The nutritional management of chronic kidney disease has progressed beyond traditional nutrient restrictions into a multi-dimensional, individualized precision era.By integrating inflammation regulation (e.g., DII), dynamic biomarker monitoring (e.g., RBP4), and body composition assessment, a closed-loop management pathway of "monitoring-intervention-reassessment" can be constructed. This promotes a shift from a "one-size-fits-all" approach to "dynamic precision." Future multi-center studies are needed to validate the clinical benefits of this pathway, ultimately enhancing patient quality of life and long-term prognosis.